Compare ADMA Biologics Inc (ADMA) vs Global X Cybersecurity (BUG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Global X Cybersecurity — how do they compare? ADMA Biologics Inc trades at $9.19 (market cap $2.13B), while Global X Cybersecurity trades at $39.46. The key difference: Global X Cybersecurity is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | BUG | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $20.38 | $40.67 |
52-Week Low | $7.60 | $23.30 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
BUG trades at $40.67, up 3.41% today, with a bullish technical trend supported by moving averages but overbought RSI levels. The cybersecurity ETF benefits from sector tailwinds as global spending exceeds $300 billion in 2026 (24/7 Wall Street, 2026-07-03), though AI disruption poses challenges. Key support lies at $39, with resistance at $41.
Outlook is mixed: strong sector growth supports upside, but premium valuations and AI-driven competitive threats present risks. Investors should weigh robust cybersecurity demand against potential earnings compression from rapid technological shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Global X Cybersecurity
BUG is a thematic ETF that invests in companies at the forefront of the global cybersecurity industry. It provides concentrated exposure to leaders in network security, endpoint protection, and cloud security, such as Fortinet, Akamai, and CrowdStrike.
Read more on BUG →
